Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Real Time RT-PCR02:57

Real Time RT-PCR

57.5K
Real-time reverse transcription-polymerase chain reaction, or Real-time RT-PCR, is an analytical tool used to determine the expression level of target genes. The method involves converting mRNA to complementary DNA with the help of an enzyme known as reverse transcriptase, followed by the PCR amplification of the cDNA. These two processes can be performed simultaneously in a single tube or separately as a two-step reaction.
The real-time quantification of the number of amplified products is...
57.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incremental Prognostic Value of Cardiac Magnetic Resonance Beyond Biomarker Staging in Transthyretin Cardiac Amyloidosis.

European heart journal. Cardiovascular Imaging·2026
Same author

Technical Considerations of Pharmacokinetic Assays for LNP-mRNA Drug Products by RT-qPCR.

The AAPS journal·2025
Same author

Cellular Immunogenicity Assessments in CAR-T Cell Therapies: Current Insights and Future Directions.

The AAPS journal·2025
Same author

Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis.

Clinical pharmacology and therapeutics·2024
Same author

Unravelling complexity: A case of progressive cardiac involvement in hereditary amyloidosis after liver transplant.

Kardiologia polska·2024
Same author

Moving From Transactional to Relational: How Funders Can Work in Partnership With Black, Indigenous and People of Color Communities.

Progress in community health partnerships : research, education, and action·2024

Related Experiment Video

Updated: Jul 24, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

Bioanalytical Methods for Characterization of CAR-T Cellular Kinetics: Comparison of PCR Assays and Matrices.

Madhan Masilamani1, Vibha Jawa1, Yanshan Dai1

  • 1Department of Clinical Pharmacology, Pharmacometrics, Disposition, and Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey, USA.

Clinical Pharmacology and Therapeutics
|July 8, 2023
PubMed
Summary

Quantitative PCR (qPCR) and droplet digital PCR (ddPCR) effectively quantify chimeric antigen receptor T-cell (CAR-T) therapy transgene levels. ddPCR offers superior sensitivity for early-phase and long-term CAR-T monitoring.

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.9K
Determination of In Vitro and Cellular Turn-on Kinetics for Fluorogenic RNA Aptamers
08:11

Determination of In Vitro and Cellular Turn-on Kinetics for Fluorogenic RNA Aptamers

Published on: August 9, 2022

1.9K

Related Experiment Videos

Last Updated: Jul 24, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.9K
Determination of In Vitro and Cellular Turn-on Kinetics for Fluorogenic RNA Aptamers
08:11

Determination of In Vitro and Cellular Turn-on Kinetics for Fluorogenic RNA Aptamers

Published on: August 9, 2022

1.9K

Area of Science:

  • Biotechnology
  • Immunotherapy
  • Molecular Diagnostics

Background:

  • Chimeric antigen receptor T-cell (CAR-T) therapies are approved for hematological malignancies, targeting CD19 and B-cell maturation antigen.
  • CAR-T therapies are unique 'living cell' treatments with distinct pharmacokinetic profiles (expansion, distribution, contraction, persistence).
  • Conventional ligand-binding assays are unsuitable for CAR-T quantitation, necessitating alternative molecular or cellular assays.

Purpose of the Study:

  • To describe and compare molecular assays for quantifying CAR-T transgene levels.
  • To evaluate the comparability of quantitative PCR (qPCR) and droplet digital PCR (ddPCR) in patient samples.
  • To assess the performance of these methods across different biological matrices (CD3+ T-cells vs. whole blood).

Main Methods:

  • Utilized quantitative PCR (qPCR) for initial transgene copy number estimation.
  • Employed droplet digital PCR (ddPCR) for absolute quantification of CAR transgene copy numbers.
  • Performed comparative analysis of qPCR and ddPCR using clinical samples from a CAR-T therapy trial and different DNA sources.

Main Results:

  • Demonstrated a good correlation between qPCR and ddPCR for amplifying the same gene in clinical CAR-T therapy samples.
  • Showed that qPCR-based transgene level amplification was consistent across different DNA sources (CD3+ T-cells and whole blood).
  • Highlighted ddPCR's high sensitivity for detecting low copy numbers, making it suitable for early-phase and long-term CAR-T monitoring.

Conclusions:

  • Both qPCR and ddPCR are viable molecular assays for CAR-T transgene quantification.
  • ddPCR offers advantages in sensitivity and ease of implementation for monitoring CAR-T therapy, especially at low transgene levels.
  • The choice of assay may depend on the specific phase of CAR-T therapy and monitoring requirements.